drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
== History == High-level vancomycin-resistant E. faecalis and E. faecium are clinical isolates first documented in Europe in 1986 and the United States in 1987. In the United States, vancomycin-resistant E. faecium was associated with 4% of healthcare-associated infections reported to the Centers for Disease Control and Prevention National Healthcare Safety Network from January 2006 to October 2007. VRE can be carried by healthy people who have come into contact with the bacteria, usually in a hospital (nosocomial infection), although it is thought that a significant percentage of intensively farmed chickens also carry VRE. Other regions have noted a similar distribution, but with increased incidence of VRE. For example, a 2006 study of nosocomial VRE revealed a rapid spread of resistance among enterococci along with an emerging shift in VRE distribution in the Middle East region, such as Iran. Treatment failures in enterococcal infections result from inadequate information regarding the glycopeptide resistance of endemic enterococci due to factors such as the presence of VanA and VanB. The study from Iran reported the first case of VRE isolates that carried the VanB gene in enterococcal strains from Iran. This study also noted the first documented isolation of nosocomial Enterococcus raffinosus and Enterococcus mundtii in the Middle East region.
Nalbuphine, sold under the brand names Nubain among others, is an opioid analgesic which is used in the treatment of pain. It is given by injection into a vein, muscle, or fat. Side effects of nalbuphine include sedation, sweatiness, clamminess, nausea, vomiting, dizziness, vertigo, dry mouth, and headache. Unlike other opioids, it has little to no capacity to cause euphoria or respiratory depression. There is also little to no incidence of dysphoria, dissociation, hallucinations, and related side effects at typical therapeutic doses. Nalbuphine is a mixed agonist/antagonist opioid modulator. Specifically, it acts as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor (MOR) and as a high-efficacy partial agonist of the κ-opioid receptor (KOR), whereas it has relatively low affinity for the δ-opioid receptor (DOR) and sigma receptors. Nalbuphine was patented in 1968 and was introduced for medical use in the United States in 1979. It is marketed in many countries throughout the world.
== A posteriori therapeutic drug monitoring == The concept of a posteriori TDM corresponds to the usual meaning of TDM in medical practice, which refers to the readjustment of the dosage of a given treatment in response to the measurement of an appropriate marker of drug exposure or effect. TDM encompasses all aspects of this feedback control, namely:
"Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes". Cardiovascular Diabetology. 21 (1): 163. doi:10.1186/s12933-022-01601-w. PMC 9400320. PMID 36002856. Patel, Krishna V.; McGuire, Darren K. (2019). "Long-term follow-up of intensive glycaemic control in type 2 diabetes". Nature Reviews Cardiology. 16 (9): 517–518. doi:10.1038/s41569-019-0241-y. PMID 31337880.
Solanum pimpinellifolium, commonly known as the currant tomato or pimp, is a wild species of tomato native to Ecuador and Peru but naturalized elsewhere, such as the Galápagos Islands. Its small fruits are edible, and it is commonly grown in gardens as an heirloom tomato, although it is considered to be wild rather than domesticated as is the commonly cultivated tomato species Solanum lycopersicum. Its genome was sequenced in 2012.
Sources: en.wikipedia.org
Since the discovery and synthesis of testosterone in the 1930s, AAS have been used by physicians for many purposes, with varying degrees of success. These can broadly be grouped into anabolic, androgenic, and other uses.
=== Music === Mass (band), an English post-punk band Mass (music), a choral composition that sets liturgical text to music Mass (Stravinsky), a composition by Igor Stravinsky Mass (Bernstein), a musical theater work by Leonard Bernstein Mass (Grotus album), 1996 Mass (The Gazette album), 2021 The Mass (album), by musical project Era Mass, a 2011 album by New Zealand musician Alastair Galbraith
=== Legal status === In January 2016, Eli Lilly submitted a new drug application to the US Food and Drug Administration (FDA) for the approval of baricitinib to treat moderately-to-severely active rheumatoid arthritis. In December 2016, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of baricitinib as a therapy for rheumatoid arthritis. European Union approval was granted in February 2017. Despite widespread expectations that the FDA would approve baricitinib for rheumatoid arthritis, in April 2017, the FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis. In March 2020, the US FDA granted breakthrough therapy designation to baricitinib for the treatment of alopecia areata and granted approval in June 2022. The efficacy and safety of baricitinib in alopecia areata was studied in two randomized, double-blind, placebo-controlled trials (Trial AA-1 and Trial AA-2) with participants who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than six months. Participants in these trials received either a placebo, 2 milligrams of baricitinib, or 4 milligrams of baricitinib every day. The primary measurement of efficacy for both trials was the proportion of participants who achieved at least 80% scalp hair coverage at week 36.
=== July === 1 July – First Minister Humza Yousaf announces that the SNP has changed the way it records donations after the issue was highlighted by its auditors. Having previously only kept online records of donations under £250, the party will now keep documented records of the donations. 2 July – During an appearance on BBC Radio Scotland's The Sunday Show, Conservative MSP Jamie Greene alleges that he lost his post in the Shadow Cabinet of Douglas Ross for supporting the Scottish Government's controversial Gender Recognition Reform Bill. 3 July ScotRail train fares are increased by 4.8%. Members of Orkney Islands Council, a Council area of Scotland, vote 15–6 in favour of investigating alternative methods of government that includes the potential to become a crown dependency of the UK or a self-governing territory of Norway. 5 July King Charles III is presented with the Honours of Scotland during a ceremony held at Edinburgh's St Giles Cathedral. SNP MP Angus McNeil is suspended from the party for a week following an argument with the party's chief whip, Brendan O'Hara, after he allegedly threatened O'Hara. 6 July The Scottish and UK governments confirm plans to collaborate on new legislation to prevent landlords excluding parents and people on benefits from renting properties. The 2023 Tiree Music Festival is cancelled a day before events are due to begin due to "extreme weather". 7 July The Scottish Government urges Westminster to decriminalise the personal possession of all illegal drugs, and puts forward a number of proposals for the managed use of drugs.
Sources: en.wikipedia.org
The UK government announces it will overhaul what it describes as the "feudal" leasehold system in England and Wales by the end of the current parliament. A security incident at Buchanan bus station in the centre of Glasgow leads to the evacuation of the area and anti-terror police being called out; around three men are arrested in connection with the incident. 22 November Ofgem announces the price of an average energy bill will rise by £21 a year from January 2025, with the typical household paying £1,738 per year; prices are now 50% higher than pre-COVID levels. Data from the Office for National Statistics shows a 0.7% fall in retail sales during October, with people holding back on spending ahead of the budget. Downing Street indicates that Israeli Prime Minister Benjamin Netanyahu would face arrest if he travelled to the UK following the issuing of an international arrest warrant for war crimes by the International Criminal Court. The Investigatory Powers Tribunal rules that 300 people affected by the Manchester Arena bombing cannot continue with a case against MI5 in which they alleged their human rights were breached because the security agency failed to take "appropriate measures" to prevent the attack. The UK government announces plans for new "respect orders" in England and Wales, giving police and local authorities the power to ban those who persistently practice antisocial behaviour from drinking in public places or from entering town centres, with prison sentences of up to two years for those who consistently break the orders.
Surgery is the most common treatment for soft-tissue sarcomas, and usually the only way to achieve a cure. The tumor is removed leaving a safe margin of surrounding healthy tissue to decrease the chances of its recurrence. Radiation therapy may be used as a neoadjuvant before surgery to shrink tumors, or as an adjuvant after surgery to kill any cancer cells that may have been left behind. In some cases, it can be used to treat tumor that cannot be surgically removed. Chemotherapy may be used with radiation therapy either before or after surgery to try to shrink the tumor or kill any remaining cancer cells. There is evidence to suggest that doxorubicin chemotherapy as an adjuvant can reduce recurrence at the original site or elsewhere in the body. Evidence also suggests chemotherapy can increase the length of time patients live, but this is less certain evidence. The use of chemotherapy to prevent the spread of soft-tissue sarcomas has not been proven to be effective. If the cancer has spread to other areas of the body, chemotherapy may be used to shrink tumors and reduce the pain and discomfort they cause, but is unlikely to eradicate the disease. A combination of docetaxel and gemcitabine could be an effective chemotherapy regimen in patients with advanced soft-tissue sarcoma. Outcomes are better for patients who are seen (and ideally treated) at expert sarcoma centers. In the United States, these are generally found in NCI-designated cancer centers.[1]
Endogenous serum or plasma creatine concentrations in healthy adults are normally in a range of 2–12 mg/L. A single 5 gram (5000 mg) oral dose in healthy adults results in a peak plasma creatine level of approximately 120 mg/L at 1–2 hours post-ingestion. Creatine has a fairly short elimination half life, averaging just less than 3 hours, so to maintain an elevated plasma level it would be necessary to take small oral doses every 3–6 hours throughout the day.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.